TimesSquare Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

TimesSquare Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,255,160	Closed	-$191M	–	227
2019 Q2	$191M	Buy	1,255,160 +159,225	+15%	+$19.4M	1.47%	6
2019 Q1	$131M	Buy	1,095,935 +233,345	+27%	+$30M	1.01%	16
2018 Q4	$94.1M	Sell	862,590 -266,660	-24%	-$33.3M	0.81%	29
2018 Q3	$182M	Buy	1,129,250 +411,350	+57%	+$56.2M	1.21%	9
2018 Q2	$94.9M	Buy	717,900 +49,800	+7%	+$4.7M	0.63%	45
2018 Q1	$49.5M	Buy	668,100 +176,850	+36%	+$11.8M	0.34%	122
2017 Q4	$27.3M	Buy	491,250 +16,800	+4%	+$890K	0.18%	175
2017 Q3	$21.5M	Buy	+474,450	New	+$19M	0.14%	203

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TimesSquare Capital Management's SRPT Position: Q3 2019 in Review

TimesSquare Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 1,255,160 shares — an estimated $191M sold.

TimesSquare Capital Management first reported a position in SRPT in Q3 2017 and held it in 8 quarters. The position peaked at $191M in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

TimesSquare Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
TimesSquare Capital Management sold 1,255,160 Sarepta Therapeutics shares in Q3 2019, an estimated $191M.
TimesSquare Capital Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 8 quarters.
TimesSquare Capital Management's Sarepta Therapeutics position peaked at $191M in Q2 2019.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on TimesSquare Capital Management's 13F filing for Q3 2019, filed 5 Nov 2019.